1 - L1_raltegravir (DOE)

This tender pertains to the supply of L1_raltegravir (DOE). The specific nature of 'DOE' in this context is not detailed in the provided information, but it likely refers to a specific formulation, grade, or application requirement for the raltegravir compound. Raltegravir is an antiretroviral medication used in the treatment of HIV infection. Tenders for pharmaceutical compounds typically involve stringent quality control, adherence to pharmacopoeia standards, and specific packaging and delivery requirements. Potential bidders are expected to demonstrate their capability to meet these standards. Further details regarding the quantity, delivery timelines, evaluation criteria, and specific technical specifications for L1_raltegravir (DOE) would be available in the full tender documentation. This procurement likely falls within the healthcare or pharmaceutical sector, aiming to ensure the availability of essential medicines. Interested parties should review the complete tender package to understand the full scope of work and eligibility criteria. The tender is likely issued by a government health agency or a large healthcare organization seeking to procure this specific pharmaceutical ingredient or finished product.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Spain, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.